Nach Genre filtern
- 30 - The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
Many listeners may be familiar with the FDA's Adverse Event Reporting System or FAERS. Data in FAERS supports the FDA's post-marketing safety surveillance program for drug products and therapeutic biologic products. Recently, CDER's Office of Surveillance and Epidemiology created and released a tool that makes FAERS data easier to query and retrieve. This new interactive dashboard is designed to expand access of FAERS data to the general public.
Dr. Janet Woodcock, Director of the FDA Center for Drug Evaluation and Research, discusses the advantages of the tool as well as its limitations.
Sun, 29 Oct 2017 - 00min - 29 - FDA D.I.S.C.O.: Rucaparib in Ovarian CancerWed, 17 May 2017 - 00min
- 28 - FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
Sun, 07 Jan 2018 - 00min - 27 - FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung CancerFri, 28 Jul 2017 - 00min
- 26 - FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung CancerTue, 25 Jul 2017 - 00min
- 25 - FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment ApprovalTue, 30 May 2017 - 00min
- 24 - FDA D.I.S.C.O.: Avelumab in Merkel Cell CarcinomaMon, 22 May 2017 - 00min
- 23 - FDA D.I.S.C.O.: Niraparib in Ovarian CancerThu, 18 May 2017 - 00min
- 22 - Pinpointing the Top Questions about Biosimilars in RheumatologyThu, 30 Nov 2017 - 00min
- 20 - The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
The FDA has made strides in improving transparency and data access, and has implemented tools to allow the pharmaceutical industry and the public to transform raw data into usable information. One of these tools is called the FDA Adverse Event Reporting System (FAERS) Public Dashboard. In this episode, the architects of the FAERS Public Dashboard – Deputy Director of the Regulatory Science Staff Suranjan De, and Acting Team Lead in Regulatory Science Information Sanjay Sahoo—both of CDER’s Office of Surveillance and Epidemiology, highlight their work with this new online tool.
Tue, 31 Jul 2018 - 00min - 19 - FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
The Food and Drug Administration (FDA) is warning that the medicine lamotrigine (Lamictal) for seizures and bipolar disorder can cause a rare but very serious reaction that excessively activates the body’s infection-fighting immune system. This can cause severe inflammation throughout the body and lead to hospitalization and death, especially if the reaction is not diagnosed and treated quickly.
A link to the full communication detailing specific information for health care professionals and a list of FDA-approved GBCAs can be found at www.fda.gov/Drugs/DrugSafety
Released 4/25/2018
Fri, 04 May 2018 - 00min - 17 - FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.
Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety.
Released 12/19/2017
Fri, 05 Jan 2018 - 00min - 16 - FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
The FDA announced that a review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
A link to the full communication detailing information for health care professionals and the Data Summary can be found at www.fda.gov/DrugSafetyCommunications.
Released 12/20/2017
Thu, 04 Jan 2018 - 00min - 14 - FDA D.I.S.C.O.: L-Glutamine for Sickle Cell DiseaseThu, 17 Aug 2017 - 00min
- 7 - FDA: Product Confusion with Maalox Total Relief and Maalox Liquid ProductsThu, 18 Feb 2010 - 00min
- 6 - FDA: Advisory on Body Building ProductsWed, 17 Jun 2009 - 00min
- 5 - Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)Tue, 16 May 2017 - 00min
- 4 - FDA Confirms Leg and Foot Amputation Risk with Diabetes Medicine Canagliflozin
Based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. The FDA is requiring new warnings, including their most prominent Boxed Warning, be added to the canagliflozin drug labels to describe this risk.
Amputations of the toe and middle of the foot were the most common; however, amputations involving the leg, below and above the knee, also occurred. Some patients had more than one amputation, some involving both limbs.
Report side effects involving canagliflozin and other medicines to the FDA MedWatch program at fda.gov/medwatch.
A link to the full communication detailing specific information for health care professionals and the complete Data Summary can be found at fda.gov/DrugSafetyCommunications. If you have drug questions, contact the FDA at druginfo@fda.hhs.gov.
Released 5/16/2017
Tue, 16 May 2017 - 00min - 3 - FDA Restricts Use of Prescription Codeine and Tramadol Pain Medicines in Children
The Food and Drug Administration (FDA) is restricting the use of codeine and tramadol medicines in children. Codeine is approved to treat pain and cough, and tramadol is approved to treat pain. These medicines carry serious risks, including slowed or difficult breathing and death, which appear to be a greater risk in children younger than 12 years, and should not be used in these children. These medicines should also be limited in some older children. Single-ingredient codeine and all tramadol-containing products are FDA-approved only for use in adults. The FDA is also recommending against the use of codeine and tramadol medicines in breastfeeding mothers due to possible harm to their infants.
As a result, the FDA is requiring several changes to the labels of all prescription medicines containing these drugs. These new actions further limit the use of these medicines beyond the 2013 restriction of codeine use in children younger than 18 years to treat pain after surgery to remove the tonsils and/or adenoids. The FDA is now adding:
FDA’s strongest warning, called a Contraindication, to the drug labels of codeine and tramadol alerting that codeine should not be used to treat pain or cough and tramadol …Thu, 20 Apr 2017 - 00min - 1 - New Safe Use Requirements for Long-Acting Beta-Agonists (LABAs)Tue, 23 Feb 2010 - 00min
Podcasts ähnlich wie FDA Drug Information Updates
- El Partidazo de COPE COPE
- Herrera en COPE COPE
- The Dan Bongino Show Cumulus Podcast Network | Dan Bongino
- Es la Mañana de Federico esRadio
- La Noche de Dieter esRadio
- Hondelatte Raconte - Christophe Hondelatte Europe 1
- Dateline NBC NBC News
- 財經一路發 News98
- La rosa de los vientos OndaCero
- Más de uno OndaCero
- La Zanzara Radio 24
- Les Grosses Têtes RTL
- L'Heure Du Crime RTL
- El Larguero SER Podcast
- Nadie Sabe Nada SER Podcast
- SER Historia SER Podcast
- Todo Concostrina SER Podcast
- 安住紳一郎の日曜天国 TBS RADIO
- TED Talks Daily TED
- アンガールズのジャンピン[オールナイトニッポンPODCAST] ニッポン放送
- 辛坊治郎 ズーム そこまで言うか! ニッポン放送
- 飯田浩司のOK! Cozy up! Podcast ニッポン放送
- 吳淡如人生實用商學院 吳淡如
- 武田鉄矢・今朝の三枚おろし 文化放送PodcastQR